| Cat. No. |
Product Name |
Information |
| PC-63549 |
Maralixibat chloride
ASBT inhibitor
|
Maralixibat chloride (Lopixibat chloride, LUM-001, HP-625) is a potent, selective, oral inhibitor of apical sodium-dependent bile acid transporter (ASBT, ileal bile acid transporter (IBAT) and SLC10A2). |
| PC-63453 |
A4250
ASBT inhibitor
|
A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH.. |
| PC-61418 |
Volixibat
ASBT inhibitor
|
Volixibat (SHP626, SAR548304, LUM002) is a highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH). |
| PC-61407 |
Elobixibat
ASBT inhibitor
|
Elobixibat (A3309, AZD7806, AJG-533) is an orally available, potent and selective apical sodium-dependent bile acid transporter (ASBT, ileal bile acid transporter (IBAT) and SLC10A2) inhibitor with IC50 of 0.53 nM, 0.13 nM, and 5.8 nM for human, mouse, and canine IBAT respectively. |
| PC-61384 |
Linerixibat
ASBT inhibitor
|
Linerixibat (GSK2330672) is a highly potent, selective, ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor with IC50 of 2.1/1.9 nM for mouse/rat ASBT, respectively. |
| PC-23610 |
Elobixibat hydrate
ASBT inhibitor
|
Elobixibat hydrate (A3309, AZD7806, AJG-533) is an orally available, potent and selective apical sodium-dependent bile acid transporter (ASBT, ileal bile acid transporter (IBAT) and SLC10A2) inhibitor with IC50 of 0.53 nM, 0.13 nM, and 5.8 nM for human, mouse, and canine IBAT respectively. |
| PC-23585 |
S1647
SOAT inhibitor
|
S1647 is a nonselective, multitarget inhibitor of intestinal bile acid carrier ASBT (SLC10A2), steroid sulfate carrier SOAT (SLC10A6) and hepatic bile acid carrier NTCP (SLC10A1) with IC50 of SOAT, ASBT, and NTCP of 13.4 3.5, and 10.4 μM, respectively. |
| PC-20411 |
A3907
ASBT inhibitor
|
A3907 is an apical sodium-dependent bile acid transporter (ASBT) inhibitor. |
| PC-61419 |
Volixibat potassium
|
A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH).. |
